Request Sample
Request Methodology
Description
Anti-Obesity Devices Market size was valued at USD 2.72 billion in 2021, growing at a CAGR of 10.1% during the forecast period 2022-2028. Obesity is a medical condition that can be defined as abnormal or excessive fat accumulation, which may have the negative effect on health. According to World Health Organisation, a person with BMI of 30 or more is generally considered as obese. Obesity increases the chances of diseases like chronic diseases, including diabetes, cardiovascular diseases, osteoarthritis, and certain types of cancers.This market mainly caused by excessive food intake, lack of physical, exercise, genetic inheritance, and rarely it occurs due to endocrine disorders, medications, and mental disorders. U.S. Food and Drug Administration approved the anti-obesity devices for the treatment of obesity. Obesity can be overcome the market. Conventionally, anti-obesity devices are expected to dominate in the obesity treatment market due to the ease of administration and lesser cost, and minimal invasiveness. FDA has approved the various types of anti-obesity devices, which may affect the growth of the market positively. For instance, In January 2015, FDA has approved EnteroMedics Inc.’s Vbloc Maestro system intended to treat morbid obesity. Similarly, in February 2011, Allergan got approval for anti-obesity device Lap-band, the adjustable gastric band used in the treatment of obesity. With an increasing number of device approvals, the anti-obesity market is anticipated to have a positive outlook in the forecast period. In January 2017, GI Dynamics Inc.’s EndoBarrier receives German NUB reimbursement status 1 for type 2 diabetes and obesity therapy
